Patone et al. assess the safety of the neutralizing antibody Sotrovimab in the treatment of COVID-19. Uptake of Sotrovimab was found to be unequal in different ethnic groups, however, there was no indication of an increased risk of hospitalization from adverse outcomes in those studied.
- Martina Patone
- Andrew JHL Snelling
- Julia Hippisley-Cox
